| By Cindy Wu, Asia Manufacturing Pharma |
| Monday, 19 October 2009 |
 |
Henan Lingrui Pharmaceutical is close to completion of the construction of its facility for the production of the company’s flagship product, fentanyl transdermal matrix patches, a synthetic primary μ-opioid agonist commonly used to treat chronic breakthrough cancer pain. It is approximately 80 times more potent than morphine. The new plant brought in an advanced fentanyl transdermal matrix patch technology from a German company and will be equipped with special production facilities provided by Harro Hoefliger GmbH, also a German company. Construction began in April this year.
|
|
Henan Lingrui Pharmaceutical will
|
|
|
speed up the construction of its interior structures and installation of the equipment, so as to complete the facility as early as possible.
Upon completion, the facility will produce quality fentanyl matrix patches, with an annual production capacity of 50 million patches, providing Henan Lingrui Pharmaceutical a world-class transdermal delivery technology platform and is expected to contribute significantly to the company’s bottom line.
Henan Lingrui Pharmaceutical is expected to receive production approval for fentanyl patches at the end of the year, and to record a 160 percent growth in profits for the third quarter. |
|
More than 50 of the company and its subsidiaries’ drugs are included in the 2009 National Basic Medicine List, including Bupleuri Injection, Omeprazole Enteric-coated Capsules, Nitroglycerin Injection and Aciclovir Ointment. The company is planning to increase production of these drugs, to meet strong market demand.
Want to read more?
North China Pharmaceutical plans to build US$145 million cephalosporin project
Chongqing Huapont Pharmaceutical acquires remaining interest in Beijing Nutrichem Laboratory
China’s Jiangsu Hengrui Medicine enjoys steady growth |
|
|
